01—Abstract
Summary
Summary of the 8-K filed July 2, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. filed a Current Report on Form 8-K dated June 30, 2026 (filed July 2, 2026) under Item 5.02, which covers departures of directors or certain officers, appointments, and compensatory arrangements.
The filing states that on June 30, 2026, the company announced an update to its senior management structure. The same announcement disclosed the departure of Cortney Caudill as Senior Vice President, Chief Operating Officer. The company thanked Ms. Caudill for her contributions during her tenure.
The filing does not describe the reasons for the departure, a successor, or any compensation or separation terms. The filing contains no financial results, financial statements, or quantitative figures.
It is signed by Darren Snellgrove, Senior Vice President and Chief Financial Officer. For investors, the key item is the leadership change in the operations function and the broader senior management update.
02—Key points
Key Highlights
- Item 5.02 8-K filed July 2, 2026, reporting a change in senior management (dated June 30, 2026).
- Cortney Caudill has departed as Senior Vice President, Chief Operating Officer.
- The company announced an update to its senior management structure on June 30, 2026.
- The company thanked Ms. Caudill for her contributions during her tenure.
- The filing does not disclose the reason for the departure, a successor, or separation terms.
- No financial results or quantitative financial data are included in this filing.
- Common stock trades on the Nasdaq Stock Market under the symbol HALO.
03—Questions
Frequently Asked Questions
Who left Halozyme Therapeutics?
Cortney Caudill, Senior Vice President, Chief Operating Officer, according to the filing.
When was the departure announced?
The filing states the company announced it on June 30, 2026, and the 8-K was signed and dated July 2, 2026.
Did the company name a replacement for the COO role?
The filing does not name a successor or describe interim arrangements for the Chief Operating Officer role.
What does the update to the senior management structure involve?
The filing states only that the company announced an update to its senior management structure. It does not provide details of the changes.
Does this filing include financial results?
No. The filing is a Item 5.02 current report covering officer departure and management changes, and it contains no financial statements or quantitative financial results.
04—Continue